Series B Funding Announcement
Inito, the at-home diagnostics company redefining personal health testing, has raised $29 million in a Series B round led by Bertelsmann India Investments, with participation from existing investor Fireside Ventures. This round brings Inito’s total equity funding to $45 million and marks a pivotal step as the company expands beyond fertility into a comprehensive at-home hormone and health diagnostics platform.
From Fertility to a Broader Health Platform
Inito first launched its at-home fertility monitor in 2021, enabling quantitative hormone diagnostics previously accessible only in clinical settings. Today, the company has analysed more than 30 million hormone data points, making it one of the world’s most widely used fertility systems. Its device measures FSH, Estrogen, LH and PdG, while AI models interpret hormone patterns to help users understand their reproductive health. Having supported tens of thousands of pregnancies, Inito is now broadening its platform to hormones influencing metabolism, mood, sleep, energy and overall wellbeing.
Founders on AI-Engineered Antibodies
“We’ve always believed healthcare should start at home,” said Aayush Rai and Varun AV, co-founders of Inito. “If you want to understand your hormones, you shouldn’t have to wait weeks for a lab result. AI-engineered antibodies allow us to build tests that simply were not possible before.”
Reinventing Diagnostics Through Computational Biology
Traditional antibodies, grown inside animals and manually screened, suffer from inconsistency, low sensitivity and slow production cycles. Inito’s approach uses computational protein design and machine-learning models to create synthetic antibodies that are more sensitive, stable and scalable. This innovation removes key bottlenecks that have constrained the diagnostics industry for decades and enables faster development of accurate at-home tests.
Investor Perspectives
“The future of healthcare lies at the intersection of deep science, AI, and personal wellness — and Inito is leading that shift,” said Swati Murarka, Principal, Bertelsmann India Investments. Fireside Ventures’ Kannan Sitaram added, “Inito has evolved from a breakthrough idea into a trusted women’s health brand with clinical-grade precision.”
Future Roadmap
With this new capital, Inito aims to accelerate its AI-antibody development pipeline and create next-generation at-home diagnostics across testosterone, vitamins, thyroid and more—delivering clinic-grade insights directly into consumers’ hands.
Keep building. Keep learning. Keep growing with StartupByDoc.